Immune Checkpoint Inhibitors in the Management of Lung Cancer.

Détails

ID Serval
serval:BIB_07DB0A3C900D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Immune Checkpoint Inhibitors in the Management of Lung Cancer.
Périodique
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Auteur⸱e⸱s
Zimmermann S., Peters S., Owinokoko T., Gadgeel S.M.
ISSN
1548-8756 (Electronic)
ISSN-L
1548-8748
Statut éditorial
Publié
Date de publication
23/05/2018
Peer-reviewed
Oui
Numéro
38
Pages
682-695
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Immune checkpoint inhibitors, specifically PD-1-directed agents, have changed the treatment paradigm of non-small cell lung cancer (NSCLC) and are being actively evaluated in patients with small cell lung cancer. After initial studies demonstrated survival advantage with these agents in patients with recurrent NSCLC, these agents now have demonstrated survival advantage in some patients with early-stage NSCLC. Further evaluation of these agents in combination with chemotherapy regimens and other checkpoint inhibitors is ongoing. Recent data suggest that addition of these agents to chemotherapy may improve survival compared with chemotherapy alone. Promising results have also been observed in patients with recurrent small cell lung cancer. Ongoing studies will define the role of these agents in the management of patients with small cell lung cancer. Tumor PD-L1 assessment has become standard of care since use of frontline pembrolizumab in patients with advanced NSCLC is based on tumor PD-L1 expression. Other biomarkers are being actively evaluated to identify the patients most likely to benefit from these agents. Unique adverse effects are observed with the use of immune checkpoint inhibitors. Knowledge of the adverse effects and their management is crucial in treating patients with lung cancer using immune checkpoint inhibitors.
Mots-clé
Antibodies, Monoclonal/pharmacology, Antibodies, Monoclonal/therapeutic use, Humans, Lung Neoplasms/pathology, Lung Neoplasms/therapy
Pubmed
Création de la notice
13/06/2018 7:18
Dernière modification de la notice
20/08/2019 12:30
Données d'usage